Drug Profile
Fletikumab
Alternative Names: Anti-IL-20; NN-8226; NNC0109-0012Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ZymoGenetics
- Developer Novo Nordisk
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 20 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriasis; Rheumatoid arthritis
Most Recent Events
- 02 Sep 2014 Discontinued - Phase-II for Rheumatoid arthritis in USA, Czech Republic, Argentina, Brazil, Mexico, Poland, Romania, Spain, Germany, Belgium, Hungary, United Kingdom, France and Italy (SC)
- 07 Aug 2014 Efficacy data from a phase IIb trial in Rheumatoid arthritis released by Novo Nordisk
- 24 Oct 2012 Phase-II clinical trials in Rheumatoid arthritis in Argentina (SC)